These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 37440907)
1. Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C. Zhu P; Li SY; Ding J; Fei Z; Sun SN; Zheng ZH; Wei D; Jiang J; Miao JL; Li SZ; Luo X; Zhang K; Wang B; Zhang K; Pu S; Wang QT; Zhang XY; Wen GL; Liu JO; August JT; Bian H; Chen ZN; He YW J Pharm Anal; 2023 Jun; 13(6):616-624. PubMed ID: 37440907 [TBL] [Abstract][Full Text] [Related]
2. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Wang QT; Nie Y; Sun SN; Lin T; Han RJ; Jiang J; Li Z; Li JQ; Xiao YP; Fan YY; Yuan XH; Zhang H; Zhao BB; Zeng M; Li SY; Liao HX; Zhang J; He YW Cancer Immunol Immunother; 2020 Jul; 69(7):1375-1387. PubMed ID: 32078016 [TBL] [Abstract][Full Text] [Related]
3. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY Front Immunol; 2018; 9():727. PubMed ID: 29910795 [TBL] [Abstract][Full Text] [Related]
5. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV Trials; 2018 May; 19(1):293. PubMed ID: 29801515 [TBL] [Abstract][Full Text] [Related]
6. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601 [TBL] [Abstract][Full Text] [Related]
7. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
8. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Nagato T; Lee YR; Harabuchi Y; Celis E Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. Li L; Zhou J; Dong X; Liao Q; Zhou D; Zhou Y Int Immunopharmacol; 2022 Aug; 109():108929. PubMed ID: 35700581 [TBL] [Abstract][Full Text] [Related]
10. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691 [TBL] [Abstract][Full Text] [Related]
11. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988 [TBL] [Abstract][Full Text] [Related]
13. A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention. Chen J; Liu H; Jehng T; Li Y; Chen Z; Lee KD; Shen HT; Jones L; Huang XF; Chen SY Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805690 [TBL] [Abstract][Full Text] [Related]
14. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316 [TBL] [Abstract][Full Text] [Related]